Hwang Previously Served at Mirae Asset

For the first time since its founding, Hanmi Pharmaceutical will appoint an external executive who is not from within the company as its new leader.


On March 12, Hanmi Pharmaceutical held a board meeting and nominated Sangyeon Hwang, former CEO of Chong Kun Dang Holdings and current Head of Private Equity (PE) at HB Investment, as a new inside director and candidate for CEO.

Sang-Yeon Hwang, Nominee for CEO of Hanmi Pharmaceutical.

Sang-Yeon Hwang, Nominee for CEO of Hanmi Pharmaceutical.

View original image

Hwang, recognized as an investment expert, graduated from the Department of Chemistry at Seoul National University. He previously served as Head of Research at Mirae Asset Securities, Chief Investment Officer (CIO) at Allianz Global Investors, and CEO of Chong Kun Dang Holdings. Traditionally, Hanmi Pharmaceutical has promoted its CEOs internally, so appointing an external executive to the top position is unprecedented. This move appears to be aimed at revitalizing the organization by bringing in outside talent, especially amid recent frequent conflicts and internal strife with the holding company.


At the board meeting that day, several agenda items to be presented at the regular shareholders’ meeting scheduled for March 31 were finalized. New appointments include Sangyeon Hwang as inside director, Nayoung Kim, Head of New Product Development at Hanmi Pharmaceutical (inside director), former National Assembly member Ibae Chae (outside director), and Taejun Han, President of Ghent University Global Campus (outside director). The reappointment of Taeyoon Kim as audit committee member (outside director) was also approved. Amendments to the articles of incorporation, including changes to proxy voting, the number of directors, and the replacement of directors, will also be addressed at the shareholders’ meeting.


In contrast, Jaehyun Park, the current CEO who has worked for Hanmi for 33 years, will step down when his term expires this month. The proposal for Park’s reappointment as an inside director was not included in the board’s agenda this time.


Recently, Park has experienced conflict with Dongguk Shin, Chairman of Hanyang Precision and the largest shareholder of Hanmi Science, over management intervention issues. Immediately after the board meeting, Park released a statement announcing his failure to secure another term and expressing his intention to resign.


Park stated, “I do not believe that I am the only one who must serve as a professional manager,” adding, “I hope my small resistance and plea will serve as a reminder of the importance of preserving the spirit of Lim Sungki.” He further appealed to the major shareholders and the board, saying, “While management philosophies and directions may differ, please unite in upholding the value of quality management, which is fundamental to Hanmi. Also, please ensure that no disadvantages befall the employees who supported me.” Some observers expect that, following the precedent set by former CEO Jongsu Woo, Park may serve as an advisor after his retirement.



Meanwhile, Hanmi Science, the holding company, also held a board meeting the same day and resolved to propose the appointment of Namkyu Kim, CEO of La Defense Partners, as a new non-executive director at the upcoming shareholders’ meeting. If the proposal passes, Kim will join the board alongside Chairman Dongguk Shin, who also serves as a non-executive director.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing